말단비대증 환자에서 소마토스타틴 유사체 사용에 대한 권고안

키워드

참고문헌 (59)

1. Melmed S, "Acromegaly pathogenesis and treatment", J Clin Invest, 119, pp.3189~3202 (2009)
2. Reid TJ, "Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed", Clin Endocrinol (Oxf), 72, pp.203~208 (2010)
3. Kwon O, "Nationwide survey of acromegaly in South Korea", Clin Endocrinol(Oxf), 78, pp.577~585 (2013)
4. Katznelson L, "Acromegaly : an endocrine society clinical practice guideline", J Clin Endocrinol Metab, 99, pp.3933~3951 (2014)
5. Wass JA, "The importance of locating a good pituitary surgeon", Pituitary, 2, pp.51~54 (1999)
6. Ahmed S, "Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience", Clin Endocrinol(Oxf), 50, pp.561~567 (1999)
7. Shimon I, "Transsphenoidal surgery for acromegaly : endocrinological follow-up of 98patients", Neurosurgery, 48, pp.1239~1243 (2001)[DOI]
8. McLaughlin N, "Pituitary centers of excellence", Neurosurgery, 71, pp.916~924 (2012)[DOI]
9. Kreutzer J, "Surgical management of GH-secreting pituitary adenomas : an outcome study using modern remission criteria", J Clin Endocrinol Metab, 86, pp.4072~4077 (2001)
10. 최재호, "Endocrine Outcome of Endoscopic Endonasal Transsphenoidal Surgery in Functioning Pituitary Adenomas", 대한신경외과학회지, 44(3), pp.151~155 (2008), 대한신경외과학회
11. 진상욱, "Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement", Endocrinology and Metabolism, 34(1), pp.53~62 (2019), 대한내분비학회[DOI]
12. Reichlin S, "Somatostatin", N Engl J Med, 309, pp.1495~1501 (1983)
13. Cuevas-Ramos D, "Somatostatin receptor ligands and resistance to treatment in pituitary adenomas", J Mol Endocrinol, 52, pp.R223~ (2014)[DOI]
14. Fleseriu M, "Medical management of Cushing's disease: what is the future?", Pituitary, 15, pp.330~341 (2012)
15. Reubi JC, "Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization", Cancer Res, 54, pp.3455~3459 (1994)
16. Krantic S, "Novel modalities of somatostatin actions", Eur J Endocrinol, 151, pp.643~655 (2004)
17. Maffezzoni F, "Current and future medical treatments for patients with acromegaly", Expert Opin Pharmacother, 17, pp.1631~1642 (2016)
18. Bauer W, "SMS 201-995 : a very potent and selective octapeptide analogue of somatostatin with prolonged action", Life Sci, 31, pp.1133~1140 (1982)
19. Taylor JE, "In vitro and in vivo inhibition of human small cell lung carcinoma(NCI-H69)growth by a somatostatin analogue", Biochem Biophys Res Commun, 153, pp.81~86 (1988)
20. Freda PU, "Somatostatin analogs in acromegaly", J Clin Endocrinol Metab, 87, pp.3013~3018 (2002)
21. Grass P, "Sandostatin LAR(microencapsulated octreotide acetate)in acromegaly : pharmacokinetic and pharmacodynamic relationships", Metabolism, 45(8 Suppl 1), pp.27~30 (1996)
22. McKeage K, "Octreotide long-acting release(LAR) : a review of its use in the management of acromegaly", Drugs, 63, pp.2473~2499 (2003)
23. Ciccarelli A, "Lanreotide Autogel for acromegaly : a new addition to the treatment armamentarium", Treat Endocrinol, 3, pp.77~81 (2004)
24. Taboada GF, "Quantitative analysis of somatostatin receptor subtype(SSTR1-5)gene expression levels in somatotropinomas and non-functioning pituitary adenomas", Eur J Endocrinol, 156, pp.65~74 (2007)
25. Park C, "Somatostatin(SRIF)receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas : the relationship with endogenous srif activity and response to octreotide", Endocr J, 51, pp.227~236 (2004)
26. Dietrich H, "Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers : a single-center Phase I study", Eur J Endocrinol, 166, pp.821~828 (2012)
27. Bruns C, "SOM230 : a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor(SRIF)receptor binding and a unique antisecretory profile", Eur J Endocrinol, 146, pp.707~716 (2002)
28. Wolin EM, "Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release(LAR)formulation of pasireotide(SOM230)in patients with gastroenteropancreatic neuroendocrine tumors : results from a randomized, multicenter, open-label, phase I study", Cancer Chemother Pharmacol, 72, pp.387~395 (2013)
29. Jørgensen JO, "Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist", J Clin Endocrinol Metab, 90, pp.5627~5631 (2005)
30. Conway-Campbell BL, "The extracellular domain of the growth hormone receptor interacts with coactivator activator to promote cell proliferation", Mol Endocrinol, 22, pp.2190~2202 (2008)
31. Lamberts SW, "Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995", N Engl J Med, 313, pp.1576~1580 (1985)
32. Fleseriu M, "Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly : a literature review", Pituitary, 14, pp.184~193 (2011)
33. Roelfsema F, "Therapeutic options in the management of acromegaly : focus on lanreotide Autogel", Biologics, 2, pp.463~479 (2008)
34. Mercado M, "A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR(long-acting repeatable octreotide)in the primary therapy of patients with acromegaly", Clin Endocrinol(Oxf), 66, pp.859~868 (2007)
35. Caron PJ, "Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly : results of a prospective multicenter clinical trial", J Clin Endocrinol Metab, 99, pp.1282~1290 (2014)
36. 양세정, "한국인 말단 비대증에서 long acting lanreotide의 치료", 대한내과학회지, 73(1), pp.50~57 (2007), 대한내과학회
37. Colao A, "Pasireotide versus octreotide in acromegaly : a head-to-head superiority study", J Clin Endocrinol Metab, 99, pp.791~799 (2014)
38. Sheppard M, "Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months : results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study", Pituitary, 18, pp.385~394 (2015)
39. Bronstein MD, "Switching patients with acromegaly from octreotide to pasireotide improves biochemical control : crossover extension to a randomized, double-blind, phase III study", BMC Endocr Disord, 16, pp.16~ (2016)
40. Gadelha MR, "Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly(PAOLA) : a randomised, phase 3 trial", Lancet Diabetes Endocrinol, 2, pp.875~884 (2014)
41. Holdaway IM, "Factors influencing mortality in acromegaly", J Clin Endocrinol Metab, 89, pp.667~674 (2004)
42. Zeinalizadeh M, "Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly : a stepwise approach and management", Pituitary, 18, pp.48~59 (2015)
43. Ayuk J, "Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly", J Clin Endocrinol Metab, 89, pp.1613~1617 (2004)
44. Paragliola RM, "Somatostatin receptor ligands in acromegaly : clinical response and factors predicting resistance", Pituitary, 20, pp.109~115 (2017)
45. Andries M, "A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly", Clin Endocrinol(Oxf), 68, pp.473~480 (2008)
46. 박정경, "말단비대증 환자에게서 서방형 옥트레오타이드와 란레오타이드 오토젤의 효과 비교", Endocrinology and Metabolism, 25(1), pp.25~27 (2010), 대한내분비학회
47. Giustina A, "High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial", Eur J Endocrinol, 161, pp.331~338 (2009)
48. Neggers SJ, "Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR : the LEAD study", Eur J Endocrinol, 173, pp.313~323 (2015)
49. Orlewska E, "Dosage and costs of lanreotide Autogel 120 mg administered as part of routine acromegaly care in Poland - two years of data from Lanro-Study", Endokrynol Pol, 66, pp.142~148 (2015)
50. Carlsen SM, "Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates : a prospective, randomized trial", J Clin Endocrinol Metab, 93, pp.2984~2990 (2008)
51. Fougner SL, "Preoperative octreotide treatment of acromegaly : long-term results of a randomised controlled trial", Eur J Endocrinol, 171, pp.229~235 (2014)
52. Strowski MZ, "Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice", Endocrinology, 141, pp.111~117 (2000)
53. Correa LL, "Evaluation of glucose metabolism in acromegalic patients before and after treatment with octreotide LAR", Arq Bras Endocrinol Metabol, 52, pp.55~64 (2008)
54. Caron PJ, "Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly:data from the PRIMARYS study", Clin Endocrinol (Oxf), 86, pp.541~551 (2017)
55. Kumar U, "Subtype-selective expression of the five somatostatin receptors(hSSTR1-5)in human pancreatic islet cells : a quantitative double-label immunohistochemical analysis", Diabetes, 48, pp.77~85 (1999)
56. Henry RR, "Hyperglycemia associated with pasireotide : results from a mechanistic study in healthy volunteers", J Clin Endocrinol Metab, 98, pp.3446~3453 (2013)
57. Colao A, "Managing hyperglycemia in patients with Cushing's disease treated with pasireotide : medical expert recommendations", Pituitary, 17, pp.180~186 (2014)
58. Maffei P, "Effects of octreotide exposure during pregnancy in acromegaly", Clin Endocrinol(Oxf), 72, pp.668~677 (2010)
59. Caron P, "Acromegaly and pregnancy : a retrospective multicenter study of 59 pregnancies in 46 women", J Clin Endocrinol Metab, 95, pp.4680~4687 (2010)

관련 논문AI추천